

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

BA

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 47/48, 47/42, 38/38	A1	(11) International Publication Number: WO 98/28011 (43) International Publication Date: 2 July 1998 (02.07.98)
<p>(21) International Application Number: PCT/US97/22518</p> <p>(22) International Filing Date: 18 December 1997 (18.12.97)</p> <p>(30) Priority Data: 08/770,470 20 December 1996 (20.12.96) US</p> <p>(71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US).</p> <p>(72) Inventors: PATEL, Mahesh, G.; 42 Brentwood Drive, Verona, NJ 07044 (US). GULLO, Vincent, P.; 33 Darren Woods Drive, P.O. Box 332, Liberty Corner, NJ 07938 (US). HARE, Roberta, S.; 27 Kalsen Road, Gillette, NJ 07933 (US). LOEBENGERG, David; 10 Sylvan Road, Monsey, NY 10952 (US). KWON, Heewon, Y.; 4 Hardwood Court, Warren, NJ 07059 (US). MILLER, George, H.; 25 Tara Lane, Montville, NJ 07045 (US).</p> <p>(74) Agents: HOFFMAN, Thomas, D. et al.; Schering-Plough Corporation, Patent Dept., K-6-1, 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).</p>		<p>(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>

(54) Title: COMPOSITIONS CONTAINING LIPOPHILIC OLIGOSACCHARIDE ANTIBIOTIC AND ALBUMIN



(57) Abstract

An aqueous pharmaceutical composition comprising a lipophilic oligosaccharide antibiotic salt, e.g., the N-methylglucamine salt of the everminomicin-type antibiotic of Formula (III) together with a binding agent such as human serum albumin or recombinant human albumin and a tonicity agent such as mannitol, is disclosed.

1947-1948
1949-1950
1951-1952
1953-1954
1955-1956
1957-1958
1959-1960
1961-1962
1963-1964
1965-1966
1967-1968
1969-1970
1971-1972
1973-1974
1975-1976
1977-1978
1979-1980
1981-1982
1983-1984
1985-1986
1987-1988
1989-1990
1991-1992
1993-1994
1995-1996
1997-1998
1999-2000
2001-2002
2003-2004
2005-2006
2007-2008
2009-2010
2011-2012
2013-2014
2015-2016
2017-2018
2019-2020
2021-2022
2023-2024
2025-2026
2027-2028
2029-2030
2031-2032
2033-2034
2035-2036
2037-2038
2039-2040
2041-2042
2043-2044
2045-2046
2047-2048
2049-2050
2051-2052
2053-2054
2055-2056
2057-2058
2059-2060
2061-2062
2063-2064
2065-2066
2067-2068
2069-2070
2071-2072
2073-2074
2075-2076
2077-2078
2079-2080
2081-2082
2083-2084
2085-2086
2087-2088
2089-2090
2091-2092
2093-2094
2095-2096
2097-2098
2099-2100
2101-2102
2103-2104
2105-2106
2107-2108
2109-2110
2111-2112
2113-2114
2115-2116
2117-2118
2119-2120
2121-2122
2123-2124
2125-2126
2127-2128
2129-2130
2131-2132
2133-2134
2135-2136
2137-2138
2139-2140
2141-2142
2143-2144
2145-2146
2147-2148
2149-2150
2151-2152
2153-2154
2155-2156
2157-2158
2159-2160
2161-2162
2163-2164
2165-2166
2167-2168
2169-2170
2171-2172
2173-2174
2175-2176
2177-2178
2179-2180
2181-2182
2183-2184
2185-2186
2187-2188
2189-2190
2191-2192
2193-2194
2195-2196
2197-2198
2199-2200
2201-2202
2203-2204
2205-2206
2207-2208
2209-2210
2211-2212
2213-2214
2215-2216
2217-2218
2219-2220
2221-2222
2223-2224
2225-2226
2227-2228
2229-2230
2231-2232
2233-2234
2235-2236
2237-2238
2239-2240
2241-2242
2243-2244
2245-2246
2247-2248
2249-2250
2251-2252
2253-2254
2255-2256
2257-2258
2259-2260
2261-2262
2263-2264
2265-2266
2267-2268
2269-2270
2271-2272
2273-2274
2275-2276
2277-2278
2279-2280
2281-2282
2283-2284
2285-2286
2287-2288
2289-2290
2291-2292
2293-2294
2295-2296
2297-2298
2299-2300
2301-2302
2303-2304
2305-2306
2307-2308
2309-2310
2311-2312
2313-2314
2315-2316
2317-2318
2319-2320
2321-2322
2323-2324
2325-2326
2327-2328
2329-2330
2331-2332
2333-2334
2335-2336
2337-2338
2339-2340
2341-2342
2343-2344
2345-2346
2347-2348
2349-2350
2351-2352
2353-2354
2355-2356
2357-2358
2359-2360
2361-2362
2363-2364
2365-2366
2367-2368
2369-2370
2371-2372
2373-2374
2375-2376
2377-2378
2379-2380
2381-2382
2383-2384
2385-2386
2387-2388
2389-2390
2391-2392
2393-2394
2395-2396
2397-2398
2399-2400
2401-2402
2403-2404
2405-2406
2407-2408
2409-2410
2411-2412
2413-2414
2415-2416
2417-2418
2419-2420
2421-2422
2423-2424
2425-2426
2427-2428
2429-2430
2431-2432
2433-2434
2435-2436
2437-2438
2439-2440
2441-2442
2443-2444
2445-2446
2447-2448
2449-2450
2451-2452
2453-2454
2455-2456
2457-2458
2459-2460
2461-2462
2463-2464
2465-2466
2467-2468
2469-2470
2471-2472
2473-2474
2475-2476
2477-2478
2479-2480
2481-2482
2483-2484
2485-2486
2487-2488
2489-2490
2491-2492
2493-2494
2495-2496
2497-2498
2499-2500
2501-2502
2503-2504
2505-2506
2507-2508
2509-2510
2511-2512
2513-2514
2515-2516
2517-2518
2519-2520
2521-2522
2523-2524
2525-2526
2527-2528
2529-2530
2531-2532
2533-2534
2535-2536
2537-2538
2539-2540
2541-2542
2543-2544
2545-2546
2547-2548
2549-2550
2551-2552
2553-2554
2555-2556
2557-2558
2559-2560
2561-2562
2563-2564
2565-2566
2567-2568
2569-2570
2571-2572
2573-2574
2575-2576
2577-2578
2579-2580
2581-2582
2583-2584
2585-2586
2587-2588
2589-2590
2591-2592
2593-2594
2595-2596
2597-2598
2599-2600
2601-2602
2603-2604
2605-2606
2607-2608
2609-2610
2611-2612
2613-2614
2615-2616
2617-2618
2619-2620
2621-2622
2623-2624
2625-2626
2627-2628
2629-2630
2631-2632
2633-2634
2635-2636
2637-2638
2639-2640
2641-2642
2643-2644
2645-2646
2647-2648
2649-2650
2651-2652
2653-2654
2655-2656
2657-2658
2659-2660
2661-2662
2663-2664
2665-2666
2667-2668
2669-2670
2671-2672
2673-2674
2675-2676
2677-2678
2679-2680
2681-2682
2683-2684
2685-2686
2687-2688
2689-2690
2691-2692
2693-2694
2695-2696
2697-2698
2699-2700
2701-2702
2703-2704
2705-2706
2707-2708
2709-2710
2711-2712
2713-2714
2715-2716
2717-2718
2719-2720
2721-2722
2723-2724
2725-2726
2727-2728
2729-2730
2731-2732
2733-2734
2735-2736
2737-2738
2739-2740
2741-2742
2743-2744
2745-2746
2747-2748
2749-2750
2751-2752
2753-2754
2755-2756
2757-2758
2759-2760
2761-2762
2763-2764
2765-2766
2767-2768
2769-2770
2771-2772
2773-2774
2775-2776
2777-2778
2779-2780
2781-2782
2783-2784
2785-2786
2787-2788
2789-2790
2791-2792
2793-2794
2795-2796
2797-2798
2799-2800
2801-2802
2803-2804
2805-2806
2807-2808
2809-2810
2811-2812
2813-2814
2815-2816
2817-2818
2819-2820
2821-2822
2823-2824
2825-2826
2827-2828
2829-2830
2831-2832
2833-2834
2835-2836
2837-2838
2839-2840
2841-2842
2843-2844
2845-2846
2847-2848
2849-2850
2851-2852
2853-2854
2855-2856
2857-2858
2859-2860
2861-2862
2863-2864
2865-2866
2867-2868
2869-2870
2871-2872
2873-2874
2875-2876
2877-2878
2879-2880
2881-2882
2883-2884
2885-2886
2887-2888
2889-2890
2891-2892
2893-2894
2895-2896
2897-2898
2899-2900
2901-2902
2903-2904
2905-2906
2907-2908
2909-2910
2911-2912
2913-2914
2915-2916
2917-2918
2919-2920
2921-2922
2923-2924
2925-2926
2927-2928
2929-2930
2931-2932
2933-2934
2935-2936
2937-2938
2939-2940
2941-2942
2943-2944
2945-2946
2947-2948
2949-2950
2951-2952
2953-2954
2955-2956
2957-2958
2959-2960
2961-2962
2963-2964
2965-2966
2967-2968
2969-2970
2971-2972
2973-2974
2975-2976
2977-2978
2979-2980
2981-2982
2983-2984
2985-2986
2987-2988
2989-2990
2991-2992
2993-2994
2995-2996
2997-2998
2999-3000
3001-3002
3003-3004
3005-3006
3007-3008
3009-3010
3011-3012
3013-3014
3015-3016
3017-3018
3019-3020
3021-3022
3023-3024
3025-3026
3027-3028
3029-3030
3031-3032
3033-3034
3035-3036
3037-3038
3039-3040
3041-3042
3043-3044
3045-3046
3047-3048
3049-3050
3051-3052
3053-3054
3055-3056
3057-3058
3059-3060
3061-3062
3063-3064
3065-3066
3067-3068
3069-3070
3071-3072
3073-3074
3075-3076
3077-3078
3079-3080
3081-3082
3083-3084
3085-3086
3087-3088
3089-3090
3091-3092
3093-3094
3095-3096
3097-3098
3099-3100
3101-3102
3103-3104
3105-3106
3107-3108
3109-3110
3111-3112
3113-3114
3115-3116
3117-3118
3119-3120
3121-3122
3123-3124
3125-3126
3127-3128
3129-3130
3131-3132
3133-3134
3135-3136
3137-3138
3139-3140
3141-3142
3143-3144
3145-3146
3147-3148
3149-3150
3151-3152
3153-3154
3155-3156
3157-3158
3159-3160
3161-3162
3163-3164
3165-3166
3167-3168
3169-3170
3171-3172
3173-3174
3175-3176
3177-3178
3179-3180
3181-3182
3183-3184
3185-3186
3187-3188
3189-3190
3191-3192
3193-3194
3195-3196
3197-3198
3199-3200
3201-3202
3203-3204
3205-3206
3207-3208
3209-3210
3211-3212
3213-3214
3215-3216
3217-3218
3219-3220
3221-3222
3223-3224
3225-3226
3227-3228
3229-3230
3231-3232
3233-3234
3235-3236
3237-3238
3239-3240
3241-3242
3243-3244
3245-3246
3247-3248
3249-3250
3251-3252
3253-3254
3255-3256
3257-3258
3259-3260
3261-3262
3263-3264
3265-3266
3267-3268
3269-3270
3271-3272
3273-3274
3275-3276
3277-3278
3279-3280
3281-3282
3283-3284
3285-3286
3287-3288
3289-3290
3291-3292
3293-3294
3295-3296
3297-3298
3299-3300
3301-3302
3303-3304
3305-3306
3307-3308
3309-3310
3311-3312
3313-3314
3315-3316
3317-3318
3319-3320
3321-3322
3323-3324
3325-3326
3327-3328
3329-3330
3331-3332
3333-3334
3335-3336
3337-3338
3339-3340
3341-3342
3343-3344
3345-3346
3347-3348
3349-3350
3351-3352
3353-3354
3355-3356
3357-3358
3359-3360
3361-3362
3363-3364
3365-3366
3367-3368
3369-3370
3371-3372
3373-3374
3375-3376
3377-3378
3379-3380
3381-3382
3383-3384
3385-3386
3387-3388
3389-3390
3391-3392
3393-3394
3395-3396
3397-3398
3399-3400
3401-3402
3403-3404
3405-3406
3407-3408
3409-3410
3411-3412
3413-3414
3415-3416
3417-3418
3419-3420
3421-3422
3423-3424
3425-3426
3427-3428
3429-3430
3431-3432
3433-3434
3435-3436
3437-3438
3439-3440
3441-3442
3443-3444
3445-3446
3447-3448
3449-3450
3451-3452
3453-3454
3455-3456
3457-3458
3459-3460
3461-3462
3463-3464
3465-3466
3467-3468
3469-3470
3471-3472
3473-3474
3475-3476
3477-3478
3479-3480
3481-3482
3483-3484
3485-3486
3487-3488
3489-3490
3491-3492
3493-3494
3495-3496
3497-3498
3499-3500
3501-3502
3503-3504
3505-3506
3507-3508
3509-3510
3511-3512
3513-3514
3515-3516
3517-3518
3519-3520
3521-3522
3523-3524
3525-3526
3527-3528
3529-3530
3531-3532
3533-3534
3535-3536
3537-3538
3539-3540
3541-3542
3543-3544
3545-3546
3547-3548
3549-3550
3551-3552
3553-3554
3555-3556
3557-3558
3559-3560
3561-3562
3563-3564
3565-3566
3567-3568
3569-3570
3571-3572
3573-3574
3575-3576
3577-3578
3579-3580
3581-3582
3583-3584
3585-3586
3587-3588
3589-3590
3591-3592
3593-3594
3595-3596
3597-3598
3599-3600
3601-3602
3603-3604
3605-3606
3607-3608
3609-3610
3611-3612
3613-3614
3615-3616
3617-3618
3619-3620
3621-3622
3623-3624
3625-3626
3627-3628
3629-3630
3631-3632
3633-3634
3635-3636
3637-3638
3639-3640
3641-3642
3643-3644
3645-3646
3647-3648
3649-3650
3651-3652
3653-3654
3655-3656
3657-3658
3659-3660
3661-3662
3663-3664
3665-3666
3667-3668
3669-3670
3671-3672
3673-3674
3675-3676
3677-3678
3679-3680
3681-3682
3683-3684
3685-3686
3687-3688
3689-3690
3691-3692
3693-3694
3695-3696
3697-3698
3699-3700
3701-3702
3703-3704
3705-3706
3707-3708
3709-3710
3711-3712
3713-3714
3715-3716
3717-3718
3719-3720
3721-3722
3723-3724
3725-3726
3727-3728
3729-3730
3731-3732
3733-3734
3735-3736
3737-3738
3739-3740
3741-3742
3743-3744
3745-3746
3747-3748
3749-3750
3751-3752
3753-3754
3755-3756
3757-3758
3759-3760
3761-3762
3763-3764
3765-3766
3767-3768
3769-3770
3771-3772
3773-3774
3775-3776
3777-3778
3779-3780
3781-3782
3783-3784
3785-3786
3787-3788
3789-3790
3791-3792
3793-3794
3795-3796
3797-3798
3799-3800
3801-3802
3803-3804
3805-3806
3807-3808
3809-3810
3811-3812
3813-3814
3815-3816
3817-3818
3819-3820
3821-3822
3823-3824
3825-3826
3827-3828
3829-3830
3831-3832
3833-3834
3835-3836
3837-3838
3839-3840
3841-3842
3843-3844
3845-3846
3847-3848
3849-3850
3851-3852
3853-3854
3855-3856
3857-3858
3859-3860
3861-3862
3863-3864
3865-3866
3867-3868
3869-3870
3871-3872
3873-3874
3875-3876
3877-3878
3879-3880
3881-3882
3883-3884
3885-3886
3887-3888
3889-3890
3891-3892
3893-3894
3895-3896
3897-3898
3899-3900
3901-3902
3903-3904
3905-3906
3907-3908
3909-3910
3911-3912
3913-3914
3915-3916
3917-3918
3919-3920
3921-3922
3923-3924
3925-3926
3927-3928
3929-3930
3931-3932
3933-3934
3935-3936
3937-3938
3939-3940
3941-3942
3943-3944
3945-3946
3947-3948
3949-3950
3951-3952
3953-3954
3955-3956
3957-3958
3959-3960
3961-3962
3963-3964
3965-3966
3967-3968
3969-3970
3971-3972
3973-3974
3975-3976
3977-3978
3979-3980
3981-3982
3983-3984
3985-3986
3987-3988
3989-3990
3991-3992
3993-3994
3995-3996
3997-3998
3999-4000
4001-4002
4003-4004
4005-4006
4007-4008
4009-4010
4011-4012
4013-4014
4015-4016
4017-4018
4019-4020
4021-4022
4023-4024
4025-4026
4027-4028
4029-4030
4031-4032
4033-4034
4035-4036
4037-4038
4039-4040
4041-4042
4043-4044
4045-4046
4047-4048
4049-4050
4051-4052
4053-4054
4055-4056
4057-4058
4059-4060
4061-4062
4063-4064
4065-4066
4067-4068
4069-4070
4071-4072
4073-4074
4075-4076
4077-4078
4079-4080
4081-4082
4083-4084
4085-4086
4087-4088
4089-4090
4091-4092
4093-4094
4095-4096
4097-4098
4099-4100
4101-4102
4103-4104
4105-4106
4107-4108
4109-4110
4111-4112
4113-4114
4115-4116
4117-4118
4119-4120
4121-4122
4123-4124
4125-4126
4127-4128
4129-4130
4131-4132
4133-4134
4135-4136
4137-4138
4139-4140
4141-4142
4143-4144
4145-4146
4147-4148
4149-4150
4151-4152
4153-4154
4155-4156
4157-4158
4159-4160
4161-4162
4163-4164
4165-4166
4167-4168
4169-4170
4171-4172
4173-4174
4175-4176
4177-4178
4179-4180
4181-4182
4183-4184
4185-4186
4187-4188
4189-4190
4191-4192
419

Various strains of bacteria such as gram-positive cocci, e.g., streptococci and enterococci as well as methicillin-resistant and methicillin-susceptible staphylococci have become, and continue to become resistant to commercially available antibiotics, e.g., vancomycin. Such sensitive and resistant strains of gram-positive bacteria are an important cause of hospital-acquired and community-acquired infections. Such bacteria are recognized as significant pathogens that cause life-threatening illnesses. The commercially available antibiotics such as methicillin, macrolides, penicillins, quinolones as well as vancomycin have limitations including the aforesaid resistance and sensitivity to gram-positive bacteria.

Thus, there is a need for pharmaceutically acceptable compositions for treating bacterial infections including methicillin-resistant and methicillin-susceptible staphylococci and vancomycin-resistant bacteria. There is also a need for improved pharmaceutically acceptable compositions containing a lipophilic oligosaccharide antibiotic active against a broad range of susceptible gram-positive and gram-negative bacterial infections, especially pharmaceutical compositions adapted for parenteral use which avoid occurrence of the adverse reaction syndrome.

BRIEF SUMMARY OF THE INVENTION

Surprisingly, we have discovered a means by which lipophilic oligosaccharide antibiotics having good antibacterial activity against susceptible gram-positive and/or gram-negative bacterial infections may be delivered to animals, especially mammals such as man, afflicted with susceptible gram-positive or gram-negative bacterial infections, to provide effective treatment and/or prevention thereof while simultaneously avoiding occurrence of the adverse reaction syndrome. This means comprises combining a lipophilic oligosaccharide antibiotic with at least about a stoichiometric amount of a specified base and an amount of a binding agent such as natural human serum albumin ("HSA") or recombinant human albumin ("rHA") sufficient to achieve efficacious delivery of the lipophilic oligosaccharide antibiotic to the serum of an animal while simultaneously avoiding adverse reaction syndrome.

The present invention provides a composition of matter comprising:

- (a) a lipophilic oligosaccharide antibiotic represented by

Formula I;

5 COMPOSITIONS CONTAINING LIPOPHILIC OLIGOSACCHARIDE ANTIBIOTIC AND ALBUMIN

BACKGROUND OF THE INVENTION


This invention relates to novel compositions of matter comprising a lipophilic oligosaccharide antibiotic salt together with a binding agent and to pharmaceutical formulations containing such compositions of matter and to methods of making and using such pharmaceutical compositions to treat and/or prevent microbial infections in animals especially mammals such as human beings.

Lipophilic oligosaccharide antibiotics including, for example, everminomicins, curamycins, avilamycins and flambamycins are members of the orthosomycin family of antibiotics which contain at least one acidic phenolic hydrogen, and two orthoester linkages associated with carbohydrate residues. See for example, A.K. Ganguly in "Kirk-Othmer, Encyclopedia of Chemical Technology", (1978), Volume 2, pp. 205-209, Third Edition, John Wiley and Sons and W.D. Ollis, et al., Tetrahedron (1979), Volume 35, pp. 105-127. These lipophilic oligosaccharide antibiotics exhibit broad spectrum biological activity against gram positive and some gram negative bacteria in various in vitro assays, and in vivo activity in animal models such as mice. It has been observed that injection of these lipophilic oligosaccharide antibiotics cause an adverse reaction syndrome. The term "adverse reaction syndrome" as used herein means symptoms of the following type observed in animals such as mice upon parenteral administration of lipophilic oligosaccharide antibiotics: incoordination, ataxia, lateral recumbency, urination, hind leg rigidity, labored breathing, and arrest.


International Publication No. WO 93/07904 discloses pharmaceutically acceptable compositions containing an amount of a pharmaceutically acceptable non-ionic surfactant and lipophilic oligosaccharide antibiotics, e.g., the everminomicin antibiotic of formula III with at least a stoichiometric amount of a base and an amount of hydroxypropyl- α -, β - or γ -cyclodextrins sufficient to achieve efficacious delivery of the oligosaccharide antibiotic to the serum of an animal while simultaneously avoiding adverse reaction syndrome.

Cyclodextrins provide efficacious delivery of the oligosaccharides antibiotic to the serum but cyclodextrins are expensive materials and not a GRAS (generally regarded as safe) material. There is a need for alternative pharmaceutically acceptable compositions of lipophilic oligosaccharide antibiotic salts which are solubilized by agents other than cyclodextrins.

BEST AVAILABLE COPY



wherein



5


X is one of NO_2 , NO , NH_2 , NHCOCH_3 , NHOH , $\text{NH}(\text{C}_2\text{H}_5)$, $\text{N}(\text{C}_2\text{H}_5)_2$, OH or H ;

R_2 is one of CH_3 , $\text{COCH}(\text{CH}_3)_2$, COCH_3 , $\text{CO}(\text{CH}_2)_3\text{CH}_3$, COCH_2CH_3 or H ;

10

R_3 is one of CH_3 or H ;

R_4 is one of COCH_3 , $\text{CH}(\text{OCH}_3)(\text{CH}_3)$, $\text{CH}(\text{OH})\text{CH}_3$, CHO , or H ;




R_6 is CH_3 or H ;
 R_7 is CH_3 or H ;
 R_8 is CH_3 , CH_2OH or H
 R_9 is CH_3 or H ;

Y is OH , CH_3 , or H ;
 W is Cl or H ; and
 Z is Cl or H .

- (b) at least about a stoichiometric amount of a base capable of forming a pharmaceutically acceptable salt with a lipophilic oligosaccharide antibiotic of Formula I;
 (c) an amount of a binding agent sufficient to achieve efficacious delivery of said lipophilic oligosaccharide antibiotic to the serum of an animal while simultaneously avoiding adverse reaction syndrome; and
 (d) 0 percent by weight (basis, the total weight of said composition) up to an iso-osmotic amount of a pharmaceutically acceptable tonicity agent.

The present invention also provides a composition of matter comprising

- (a) a compound represented by the Formula II




wherein X is one of NO_2 , NO , NHOH , NH_2 , NHCOCH_3 , NHC_2H_5 , $\text{N}(\text{C}_2\text{H}_5)_2$, OH or H

Y is OH or H

R_2 is H or CH_3

R_3 is H

R_4 is H or $\text{CH}(\text{OCH}_3)(\text{CH}_3)$
and



(b) at least about a stoichiometric amount of a base capable of forming a pharmaceutically acceptable salt with a lipophilic oligosaccharide antibiotic of Formula II;


(c) an amount of a binding agent sufficient to achieve efficacious delivery of said lipophilic oligosaccharide antibiotic to the serum of an animal while simultaneously avoiding occurrence of adverse reaction syndrome; and

(d) 0 percent by weight (basis, total weight of said composition) up to an iso-osmotic amount of a pharmaceutically acceptable tonicity agent.

The present invention further provides a composition of matter

comprising

(a) the antibiotic compound represented by Formula III



(b) at least about two equivalents of a base (per mole of the compound of Formula III) capable of forming a pharmaceutically acceptable salt of the compound

delivery of said lipophilic oligosaccharide antibiotic to the serum of an animal while simultaneously avoiding occurrence of adverse reaction syndrome; and (d) 0 percent by weight (basis, said antibiotic of Formula III) up to an iso-osmotic amount of a pharmaceutically acceptable tonicity agent.

5 A preferred composition of matter of this invention contains the following: (a) the compound represented by Formula III, (b) N-methylglucamine, (c) recombinant human albumin ("rHA"), and (d) an iso-osmotic amount of mannitol; wherein the molar ratio of (a):(b):(c) is 1: about 3-3.5: about 0.018-0.030 and the amount of the mannitol the preferred tonicity agent, is about 35 to 45% weight percent (basis total composition).

10 Pharmaceutical compositions formed by admixing a composition of matter comprising a compound represented by Formulas I, II or III and at least about a stoichiometric amount of a base capable of forming a pharmaceutically acceptable salt thereof and an amount of a binding agent with a pharmaceutically acceptable tonicity agent and pharmaceutically acceptable carriers as well as methods of using such pharmaceutical compositions for treating or preventing susceptible gram positive and gram negative bacterial infections in animals, especially mammals in need of such treating or preventing are also provided.

15 As a preferred form of the invention, the aforesaid pharmaceutical compositions are particularly applicable to parenteral administration, especially in vivo administration to human beings by the intravenous (IV) route.

20 The present invention also provides a method of preventing adverse reaction syndrome in animals following parenteral injection of a lipophilic oligosaccharide antibiotic represented by Formula I, II or III while simultaneously delivering an antiinfective amount of said antibiotic to an animal, which method comprises parenterally administering to said animal an amount of a composition of matter of this invention sufficient for such purpose together with a pharmaceutically acceptable carrier.

30 BRIEF DESCRIPTION OF THE FIGURES

Figure 1 graphically illustrates the progression, with time, of a typical fermentation of Micromonospora carbonacea, var. africana, NRRL 15099, ATCC 39149.

35 DETAILED DESCRIPTION OF THE INVENTION AND OF THE PREFERRED EMBODIMENTS

Lipophilic oligosaccharide antibiotics, for example everninomicin antibiotics, exhibit useful in vitro antibacterial activity but do not readily form complete aqueous solutions suitable for safe and effective in vivo administration (i.e.

without occurrence of adverse reaction syndrome). Moreover, salts of these antibiotics formed by admixing at least about a stoichiometric amount of a base useful in this invention, e.g. the base, N-methylglucamine ("NMG") do not form complete aqueous solutions, at useful pH values. When said salts were added to water at useful concentrations of salt, we observed that only colloidal dispersions were formed. These colloidal dispersions tended to aggregate, and eventually gelled, especially in the presence of absorbed carbon dioxide and when the pH of such colloidal dispersions was less than about 9.3. We observed that complete aqueous solutions were formed by increasing the molar ratio of NMG to the compound of Formula III from 2:1 or 3:1 up to 12:1, but that the solution so formed with the 12:1 molar ratio had an undesirably high pH, was highly buffered and was irritating. Thus, we observed that parenteral injection into rats of higher primates, such as monkeys, of an aqueous formulation containing 12 moles of NMG per one mole of the compound of Formula III did not result in adverse reaction syndrome (presumably caused by gelling and precipitation of the compound of Formula III). The formulation, produced irritation upon injection, which irritation is presumably caused by the large amount of NMG base and resulting high pH at the injection site. However, parenteral administration of a composition containing 3 or 5 moles of NMG per mole of the compound of Formula III gave rise to adverse reaction syndrome. Surprisingly, we have found that a composition of matter comprising a lipophilic oligosaccharide antibiotic compound of Formula III, a specified amount of a specific base, e.g., NMG and a specified binding agent, e.g., human serum albumin in specified amounts, provides, when admixed with pharmaceutically acceptable carriers, especially sterile water for injection, a formulation which may be used safely and effectively for in vivo administration. Surprisingly, we have found that when 1 mole of a lipophilic oligosaccharide antibiotic, e.g., the compound of Formula III was admixed with 3 moles of a suitable base, e.g., NMG, in water and with 0.027 moles of human serum albumin, a clear aqueous solution of the complex was formed and the parenteral injection of such complexes into mice did not cause adverse reaction syndrome even at high doses, i.e., 400 mg of such complex per kg of body weight. See Table 1.

As will be evident from the in vivo results summarized in Table 1 parenteral injections of the aqueous dispersions of salts, e.g., the NMG salt of the eveminomicin-type antibiotic of Formula III into mice and rats gave rise to the adverse reaction syndrome. When the aqueous solutions of one of the compositions of matter of this invention such as one containing a specified binding agent, e.g., human serum albumin with the NMG eveminomicin-type antibiotic of Formula III salts were injected into the animals the occurrence of adverse reaction syndrome was wholly avoided.

Table 2 shows that adverse reaction syndrome can be reduced or completely avoided by parenteral injection into mice of clear aqueous solutions of NMG salts of the everninomicin-type antibiotic of Formula III with the specified binding agent, human serum albumin, of this invention.

- 5 Table 3 illustrates that increasing the molar ratio of base to the everninomicin-type antibiotics of Formula III from 2:1 to 9:1 wholly eliminates the occurrence of adverse reaction syndrome at all concentrations tested upon parenteral injection into mice.

COMPARATIVE EXAMPLE 3TABLE I

THE OCCURRENCE OF ADVERSE REACTION SYNDROME AFTER
ADMINISTRATION OF AQUEOUS FORMULATIONS OF ONE MOLE OF THE
COMPOUND OF FORMULA III: AND OF
3 MOLES NMG WITH AND WITHOUT HSA¹

Mice	% Adverse Reaction Syndrome ²					
	at the following DOSES (MPK ³)					
	<u>160³</u>	<u>200³</u>	<u>320³</u>	<u>400³</u>	<u>520³</u>	
III: 3NMG	100	100	--	--	--	
III: 3NMG: 0.027HSA ⁵	--	0	0	0	40	
Rats	% Adverse Reaction Syndrome					
	at the following DOSES (MPK ⁶)					
	<u>60⁶</u>	<u>80⁶</u>	<u>100⁶</u>	<u>160⁶</u>	<u>200⁶</u>	<u>300⁶</u>
III: 3NMG	60	100	100	100	100	--
III: 3NMG: 0.027HSA ⁵	--	--	0	0	0	40

Footnotes to Table 1

1. Human serum albumin
2. Adverse Reaction Syndrome symptoms were observed in the animals within 2 minutes after IV injection. (single dose)
3. MPK is mg of drug per kg of body weight of the mice (groups of 10, CF1, average weight 20g, Harlan Sprague - Dawley fasted 18 hours.)
4. III is the everminomicin-type antibiotic compound represented by Formula III.
5. 0.027 moles HSA is equivalent to 9% w/v HSA based on an 80mg/ml solution of the compound of Formula III.
6. MPK is mg of drug per kg of body weight of the rats (groups of 5, average weight 180-200g, Charles River, fasted 18 hours)

Table 3

Effect of Concentration of Lipophilic Oligosaccharide Antibiotic NMG Salt and Molar ratio of NMG to Antibiotic upon Adverse Reaction Syndrome¹ in Mice

5

<u>Drug of Formula III</u> (Drug Concentration)	<u>% ARS¹ at the following doses (MPK²):</u>				
	<u>50</u>	<u>100</u>	<u>200</u>	<u>300</u>	<u>400</u>
III:2NMG (10 mg/ml)	0	10	50	--	--
III:2NMG (20 mg/ml)	0	20	100	100	--
III:2NMG (50 mg/ml)	70	100	--	--	--
III:3NMG (20 mg/ml)	--	0	0	0	20
III:3NMG (40 mg/ml)	--	0	0	15	40
III:3NMG (80 mg/ml)	--	--	100	--	--
III:5NMG (20 mg/ml)	--	0	0	0	--
III:5NMG (50 mg/ml)	--	--	0	--	40
III:9NMG (20 mg/ml)	--	0	0	0	0
III:9NMG (40 mg/ml)	--	0	0	0	0
III:9NMG (80 mg/ml)	--	0	--	0	0

10 Footnotes to Table 3

¹ Adverse Reaction Syndrome Symptoms observed in mice (groups of 5 to 10, CF-1, average weight 20g, Harlan Sprague Dawley, fasted 18 hours) within 2 minutes after IV (single dose) injection

² MPK is mg of the drug of Formula III per kg of body weight.

15 ³ III is everminomicin-type antibiotic compound represented by Formula III.

TABLE 4

PD 50 Values Showing Efficacy of Composition Containing the Compound of Formula III Against Bacterial Infections¹ in CF1 Mice²

DRUGS⁴

5	Organism ³	No. x 5 LD10	CFU ⁶ Mouse	A	B	C	D
	S. aureus 85111205	10	6.3x10 ⁹	9	11	26	--
	S. aureus 78100502	20	2.2x10 ⁸	12	12	6	--
	E. faecalis 88032810	10	9.7x10 ⁸	21	16	10	115
	E. faecalis 91031103 Vancomycin resistant	1.7	1.5x10 ⁹	60	60	100	49

Footnotes for Table 4

- 10 1 Injections were by IP route
- 2 CFI mice are Charles River CFI, ca 20 g while male mice
- 3 a Staphylococcus aureus 85111203 and 78100502
- b Enterococcus faecalis 803280 (Perm. APH-(3)-III) and 91031103 (Vancomycin resistant)
- 15 4 PD₅₀ Dosing routes for drugs: IV for A, B and C; SC for D in mg/Kg of body weight
- Drug A is compound of formula III: NMG:HPBCD in the molar ratio of 1:3:5 with Polysorbate 80 and mannitol in sterile water for injection (SWFI)
- 20 Drug B is the compound of formula III: NMG:HSA in the molar ratio of 1:3:0.027 and mannitol in SWFI
- Drug C is Vancomycin HCl intravenous available from Eli Lilly Co., Indianapolis; conc 10 mg vancomycin in 1 ml of SWFI).
- 25 Drug D is Amikacin
5. Multiple of one LD₁₀₀ (lethal dose to kill 100% of animals) of organism given to mice. (Measure of severity of the infection.)
6. Amount of organism administered to mice in Colony Forming Units ("CFU's").
- 30

Perhaps even more surprisingly, we observed that the Minimum Inhibitory Concentrations ("MIC") in the in vitro models, and the 50% protective dose ("PD₅₀") values in an in vivo mouse protection model, of the composition of 0.027 human serum albumin in combination with one mole of the compound of Formula III and 3 moles of NMG (Drug B in Table 4) were essentially the same as the MICs and

PD₅₀ values for the compound of Formula III and for those of the NMG salt of the compound of Formula III with HP β CD in said model (Drug A in Table 4). See Table 4 for PD₅₀ values for the compositions of the compound of formula III including a preferred composition of the present invention (Drug B) compared to those for vancomycin (Drug C) and amikacin (Drug D).

Thus, we have surprisingly discovered improved pharmaceutically acceptable compositions of matter containing a lipophilic oligosaccharide antibiotic salt and a binding agent such as HSA which allows effective delivery of such antibiotic to the serum of an animal such as a mammal especially a man afflicted with a bacterial infection susceptible to treatment by such lipophilic oligosaccharide antibiotics of Formulas I, II and III.

The term "binding agent" as used herein means a substance which has sufficient free highly lipophilic binding sites to achieve efficacious delivery of the lipophilic oligosaccharide antibiotics of formulas I, II and III to the serum of an animal while simultaneously avoiding occurrence of adverse reaction syndrome. Typically suitable binding agents include any protein with highly lipophilic binding sites as evidenced by its effective binding with fatty acids. Such proteins include natural human serum albumin ("HSA") and recombinant human albumin ("rHA"). HSA is produced as a product from fractions of collected blood. Human serum albumin is available from Armour Pharmaceutical Div., Rhone-Poulenc Rorer, 500 Arcola Rd., Collegeville, PA 19426 and Fluka-Chemika-BioChemika, Industriestrasse 25, CH-9470 Buchs, Switzerland. rHA is prepared by use of recombinant techniques such as described in EP 0 683 233 published 22 November 1995 and is commercially available from Delta Biotechnology Ltd., Nottingham NG71FD, Great Britain. Other binding agents include deoxycholic acid and salts thereof, for example, sodium deoxycholate which is available from Sigma Chemicals Co., P.O. Box 14508, St. Louis, MO. 63178.


The moles of binding agent per mole of the compound of formula I, II or III varies from about 0.006 to about 0.03. If the binding agent is substantially free of impurities (i.e., contains <1-5%) such as fatty acids bound to the binding site of the agent, only about 0.006 moles (per mole of compound of formula I, II, or III) of such purified binding agent would be needed to achieve effective delivery of the compounds of formula I, II or III to the serum of the mammals. Amounts of binding agent above about 0.03 moles per mole of compound of formulas I, II or III have no further beneficial effect. The preferred binding agent is rHA which is readily available free of impurities such as fatty acids binding to it; about 0.006 moles of rHA (2% w/v based on 80 mg/ml of the compound of formula III) is needed to effectively transfer the compound of formula I, II or III to the serum of a mammal.

The term "tonicity agent", as used herein means an agent which allows the pharmaceutical compositions of the present invention to have an osmotic pressure compatible with human serum. Typically suitable tonicity agents, which may be present in the preferred pharmaceutical compositions of the present invention, include mannitol, sodium chloride, glycine and dextrose. The preferred tonicity agent (when one is used,) is mannitol but any pharmaceutically acceptable tonicity agent would also be acceptable.

The term "iso-osmotic" as used herein in reference to the amount of tonicity agent means the amount of the tonicity agent sufficient to make the pharmaceutical compositions of the present invention upon administration to a mammal iso-osmotic with the plasma of such a mammal. The iso-osmotic amount of tonicity agent varies with the tonicity agent used and may conveniently be measured in accordance with the procedures described in "Remington's Pharmaceutical Sciences" A.R. Gennaro, ed, 1990, 18th Edition, Mack Publishing Co., Easton, PA, Chapter 79 entitled "Tonicity, Osmoticity, Osmolality and Osmolarity", pages 1481-1498 at 1488-1491. The iso-osmotic amount of mannitol, the preferred tonicity agent, is preferably about 35 to 45% by weight basis total weight of all ingredients in the composition.


The bases found suitable for use in the present invention are those which form pharmaceutically acceptable salts of the lipophilic oligosaccharide antibiotics of Formulas I, II or III and include suitable organic and inorganic bases. Suitable organic bases include primary, secondary and tertiary alkyl amines, alkanolamines, aromatic amines, alkylaromatic amines and cyclic amines. Exemplary organic amines include the pharmaceutically acceptable bases selected from chlorprocaine, procaine, piperazine, glucamine, N-methylglucamine, N,N-dimethyl glucamine ethylenediamine, diethanolamine, diisopropylamine, diethylamine, N-benzyl-2-phenylethylamine, N-N'dibenzylethylenediamine, choline, clemizole, tris(hydroxymethyl)aminomethane, or D-glucosamine. The preferred organic bases include N-methyl glucamine ("NMG"), diethanolamine, and tris(hydroxymethyl) aminomethane ("TRIS"). Use of NMG in this invention is more preferred. The suitable inorganic bases include alkali metal hydroxides such as sodium hydroxide. The bases found useful in the preparation of compositions of matter of the present invention produce aqueous solutions having a pH of at least about 9.3. Lysine forms aqueous solutions having a pH of less than 9.3 and thus lysine is not a suitable base for the present invention. Divalent metal hydroxides such as the alkaline earth hydroxides, calcium hydroxide and barium hydroxide did not form aqueous solutions of the lipophilic oligosaccharide antibiotics of Formulas I, II or III in the presence of a binding agent having a pH of at least about 9.3 and were unacceptable as bases for use in the present invention.

The term "at least about a stoichiometric amount" as used herein in reference to the bases useful in this invention means the amount of base needed to substantially completely react with (i.e. result in more than 99% complete reaction) the acidic phenolic hydrogens of the lipophilic oligosaccharides antibiotics of Formulas I, II, III having one or two or three phenolic hydrogens. For the compounds of Formulas I and II wherein $R_5 = H$, there is only one phenolic acidic hydrogen per molecule and the stoichiometric amount of the pharmaceutically acceptable bases of this invention is at least about one mole of such base up to 12 moles of such bases. For the compounds represented by Formula I and II wherein



10

and for the compounds of Formula III there are three acidic phenolic hydrogens per mole of such compounds, the stoichiometric amount of base required to completely react with the three acidic phenolic hydrogens is at least one up to about 12 moles of the pharmaceutically acceptable bases useful in this invention. For the preferred lipophilic oligosaccharide antibiotics of Formulas I, and II wherein



15

and those of Formula III, it is preferred to use about one to 6 moles, and it is more preferred to use about 2.0 to 3.5 moles and most preferred to use about 2 to about 3 moles of a pharmaceutically acceptable base such as NMG to maintain the pH of an aqueous solution thereof at a value of about 9.3 as opposed to solutions having a higher pH, and which solutions were highly buffered when 6-12 moles of NMG were used.

20

The term "lipophilic oligosaccharide antibiotic" as used herein means selected lipophilic members of the orthosomycin family of antibiotics, more particularly flambamycin, the everminomicins, everminomicin-type antibiotics, curamycin and the avilamycin A-N antibiotics.

25

Flambamycin, a lipophilic oligosaccharide antibiotic produced by Streptomyces hygroscopicus DS 23230, whose structural Formula is that of Formula

I wherein $R_1=R_5=H$, $Y=OH$, $R_2=COCH(CH_3)_2$, $R_3=R_6=R_7=R_8=R_9=CH_3$, $R_4=COCH_3$ and $W=Z=Cl$ is disclosed by W.D. Ollis in Tetrahedron, (1979), **35**, 105-127.

Curamycin A is a flambamycin antibiotic (having a structural Formula represented by Formula I wherein $R_1, R_3, R_4, R_5, R_6, R_7, R_8, R_9, W$ and Z are the same as for flambamycin except $R_2=COCH_3$ and $Y=H$. See O.L. Galamarine et al. Tetrahedron (1961), **15**, 76 and V. Deulofer et al., Anales de Quimica (1972), **68**, 789.

Avilamycin A-N antibiotics are lipophilic oligosaccharide antibiotics isolated from an antibiotic complex produced by cultures of the organism

Streptomyces viridochromogenes, NRRL 2860. See J.L. Mertz et al. The Journal of Antibiotics (July 1986) Vol 39 (No. 7) 877-887. The structural Formulas for the avilamycin A-N antibiotics are represented by Formula I wherein, $R_1=R_5=H$, $Y=H$, $R_2=COCH(CH_3)_2$, $COCH_3$, $CO(CH_2)_3CH_3$, $COCH_2CH_3$ or H , $R_3=CH_3$, $R_4=COCH_3$, $CH(OH)CH_3$ or CHO and $R_6=CH_3$ or H ; $R_7=CH_3$ or H ; $R_8=CH_3$, CH_2OH or H ; $R_9=CH_3$ or H and $W=H$ or Cl and $Z=Cl$.

The everminomicin antibiotics useful in this invention include the everminomicins B, C and D isolated from the antibiotic complex produced by the organism, Micromonospora carbonacea var. carbonacea NRRL 2972 and a variety thereof M. carbonacea var. aurantiaca NRRL 2997 as described in USP 3,499,078.

The everminomicin derivatives having a nitrous, hydroxylation or amino moiety in place of the moiety in everminomicins B, C and D may be obtained by reduction of the nitro moiety in everminomicins B, C and D in accordance with the procedures of USP 4,006,225. A preferred everminomicin is N-acetylaminoeverminomicin-D and is represented by Formula II wherein $X=NHCOCH_3$, $Y=H$; $R_4=CH(OCH_3)(CH_3)$;


$R_3=R_5=H$ and $R_2=CH_3$. N-acetylaminoeverminomicin D and its di N-methylglucamine salt may be prepared by the procedures of USP 4,129,720 which discloses reduction of the nitro moiety of everminomicins B, C and D to produce the amino derivatives which are subsequently converted into the N-acyl e.g. N-acetyl, N-alkyl, e.g. $NH(C_2H_5)$, or N,N-dialkyl, e.g. $N(C_2H_5)_2$, derivatives. The preparation of the N-acyl-N-hydroxylamino everminomicin B, C and D derivatives and pharmaceutically acceptable salts thereof are also described. The preparation of Everminomicin 7 represented by Formula II wherein $X=OH$, $Y=H$,

$R_4=CH(OCH_3)(CH_3)$, $R_5=H$ and $R_2=CH_3$ is disclosed by A.K. Ganguly et al. in J. Chem. Soc., Chem. Comm., 1980, 56-58.

The "everminomicin-type" antibiotics are those lipophilic oligosaccharide antibiotics represented by Formula II wherein $X=NO_2$, NO , NH_2 , OH , $NHCOCH_3$, NHC_2H_5 , $N(C_2H_5)_2$, $NHOH$ or H , $Y=OH$, $R_2=CH_3$ or H ; $R_3=H$,


$R_4 = \text{CH}(\text{OCH}_3)(\text{CH}_3)$ or H and

$R_5 = \text{H}$ or



The compounds of Formula II wherein $X = \text{NO}_2$ or NH_2 , $Y = \text{OH}$

$R_2 = R_3 = R_4 = \text{H}$, and $R_5 =$




are isolated from an antibiotic 13-384

- 5 complex produced by fermentation of the organism Micromonospora carbonacea var. africana, NRRL 15099, ATCC 39149. Antibiotic components 1 (Formula II, $X = \text{NO}_2$ and Y , R_2 , R_3 , R_4 and R_5 are each defined as hereinabove in reference to antibiotic 13-384) and 5 (Formula II, $X = \text{NH}_2$ and Y , R_2 , R_3 , R_4 , and R_5 are as defined as hereinabove in reference to antibiotic 13-384) disclosed in USP 4,597,968 and
- 10 4,735,903 have the structural Formulas disclosed by AK Ganguly et al. in Heterocycles (1984) Vol. 28 (No. 1) p 83-88. The eveminomicin-type antibiotics of Formula II wherein $X = \text{H}$, NHOH , NHCOCH_3 and acyl and alkyl derivatives thereof are described in USP 4,622,314 and 4,767,748.

The preferred compositions of matter of this invention include compounds of Formula II wherein $R_3=H$.

and	X	Y	R_4	R_5	R_2
	NO ₂	OH	CH(OCH ₃)(CH ₃)	H	CH ₃
	OH	H	"	"	"
	NO ₂	H	H	"	"
	NO ₂	H	CH(OCH ₃)(CH ₃)	"	"
	NHCOCH ₃	H	"	"	"
	NO ₂	OH	H	"	H



NHOH

NHCOCH₃

NH₂

NHC₂H₅

N(C₂H₅)₂

5

The most preferred everninomicin-type antibiotic is named 56-deacetyl-57-demethyl-45-O-de(2-methyl-1-oxopropyl)-12-O-(2,3,6-trideoxy-3-C-methyl-4-O-methyl-3-nitro- α -L-arabino-hexopyransoyl)-flambamycin 56-(2,4-dihydroxy-6-methylbenzoate) having the molecular Formula of: C₇₀H₉₇NO₃₈Cl₂ and the molecular weight of 1629 and is represented by Formula III.

10

The preferred compound of the Formula III may be obtained by fermentation of *Micromonospora carbonacea* var. *africana* NRRL 15099, ATCC 39149 or, more preferably, by an improved strain thereof, obtained as hereinafter described.

15

Utilizing the strain SCC 1413 of the culture NRRL 15099, ATCC 39149, the preferred compound of the Formula III may suitably be obtained by the procedures outlined in Example I of USP 4,597,968. In a specific example, in accordance with this procedure, the initial stage inoculum for the fermentation of strain SCC 1413 was prepared by transferring 2.5 ml of a frozen whole broth of 50 ml of the germination medium in 250 ml Erlenmeyer flasks. The germination medium consisted of beef extract, 0.3%; tryptone, 0.5%; dextrose, 0.1%; potato

20

starch, 2.4%; yeast extract, 0.5%; and calcium carbonate, 0.2%. The pH of the medium was adjusted to 7.5 prior to sterilization. The flasks were incubated at 30°C on a gyratory shaker at 300 rpm for 48 hours. For the second stage germination, 2 liter Erlenmeyer flasks containing 350 ml of the same medium were inoculated with a 5% volume of the first stage germination. The conditions for incubation were the same as before. A third inoculum stage was employed for all stirred tank fermentations and was prepared by a 24 hour incubation of the culture under the same conditions as employed for the second stage.

Ten liter fermentations were initially carried out in 14 liter NBS Laboratory Fermentors in a fermentation medium containing yeast extract, 0.5%; casein hydrolysate, 0.5%; cerelose, 1%; soluble starch, 2.0%; calcium carbonate, 0.4%; and cobalt chloride, 0.24 mg %. The pH of the medium was adjusted to 6.7 before sterilization and to 7.0 before inoculation. The third stage inoculum (2.5%) was used to initiate the fermentation which was conducted at 30°C with 0.35 vvm of air and 350 rpm agitation.

During the course of the fermentation, antibiotic production was monitored every 24 hours by bioassay of the whole broth against Staphylococcus aureus 209P (pH of the agar, 7.0) and Escherichia coli ATCC 10536 (pH of the agar, 8.0). The growth of the producing organism (packed cell volume), pH and dissolved oxygen levels were also determined either intermittantly or continuously. The course of a typical 10 liter tank fermentation is illustrated in Fig. 1.

We have developed an improved strain from SCC1413, NRRL 15099, ATCC 39149 using standard mutagenesis agents and obtained strains producing improved yields of the preferred eveminomicin-type antibiotic compound of the Formula III. In a specific example, the parent strain SCC 1413, NRRL 15099, ATCC 39149 was exposed to an amount of the mutagenesis agent, N-nitrosoguanidine (NTG) sufficient to kill 90% of a culture of SCC 1413, ATCC 39149, NRRL 15099. Fifteen hundred surviving isolates were examined for enhanced biological activity against S. aureus and E. coli to determine which isolates exhibited improved production of the desired antibiotic of Formula III. The test procedure employed to determine enhanced activity was as follows: Single colony isolates were germinated in test tubes containing 10 ml of germination media of Example 1 of USP 4,597,968 and shaken at 250 rpm on a gyratory shaker at 30° C for 48 hours. Fermentation studies were initiated by transferring 2.5 ml of the seed to 250 ml Erlenmeyer flasks containing 50 ml of fermentation media and incubating at 30° C for 96 hours at 250 rpm on a gyratory shaker. The antibiotic obtained following fermentation was then assayed for improved antibiotic production by assessing the activity against S. aureus and E. coli and isolates giving improved yields of the

desired antibiotic were identified. The results for a representative improved isolate, designated herein as strain SCC 1631, are given in Table 5.

The foregoing strain-development procedure was repeated by subjecting the representative improved isolate, SCC 1631, to a further exposure to NTG, again in an amount sufficient to kill 90% of the cultures, followed by selection of the isolates on agar plates containing 150 $\mu\text{g/mL}$ of everninomicin D. Isolates giving enhanced production of the desired antibiotic were again selected by assessing biological activity thereof against *S. aureus* and *E. coli*. One such isolate, herein designated strain SCC 1756, was then utilized to produce the preferred antibiotic of Formula III.

Further, NTG mutagenesis of SCC 1756 yielded our current production strain, SCC 2146.

In the foregoing mutation procedures, the protocols for both studies were as previously described hereinabove. For the latter two mutation studies, fermentation broths were extracted with ethyl acetate and the concentrates were chromatographed on Whatman LKGDF thin layer plates in a solvent system consisting of chloroform:methanol (9:1v/v) followed by bioautography against *S. aureus* and *E. coli* to confirm the production of all components of the antibiotic complex. To follow increased titers of the compound of Formula III, thin layer plates were examined by using the Shimadzu GS-930 TLC plate scanner and quantitating the higher producing extracts by using HPLC. Combined titers are defined as the sum of the compound of Formula III (antibiotic 13-384, component 1 of USP 4,597,968) and the nitroso analog of said component 1, i.e., antibiotic 13-384 component 1a.

Early observations indicated that although the parent strain SCC 1413 grew rapidly at 34°C, antibiotic production was optimal if the temperature was lower. This phenomenon was investigated as a means of fermentation optimization. Results of the temperature study indicated that optimal production was obtained when the temperature was lowered from 34°C to 30°C after 24 hours of incubation. All subsequent work in stirred tanks followed the protocol of incubating the fermentation at 34°C for 24 hours followed by lowering the temperature to 30°C for the duration of the fermentation run.

Media studies were conducted in conjunction with the isolation of the improved production strains. Carbon and nitrogen source substitutions were investigated as well as the addition of minerals and other complex nutrients. Replacement of casein hydrolysate by either meat or fish peptone and substituting potato dextrin (PDP 650) for soluble starch enhanced antibiotic production using strains SCC 1413 and SCC 1631. Subsequent enhancements in the production of the compound of Formula III were observed with the addition of corn steep liquor

and nickel (II) chloride in studies with strain SCC 1756. The current production fermentation media (4I + 1/2 Ni) optimized for the compound of Formula III contains glucose, 2.2 weight %; PDP 650 dextrin, 4.0 weight %; yeast extract, 0.5 weight %; meat peptone, 0.6 weight %; corn steep liquor, 0.5% vol., nickel chloride, 2.5×10^{-6} M; and calcium carbonate, 0.4 weight %. The pH of the medium was adjusted to 6.7 before the addition of calcium carbonate. Table 6 shows a comparison of the titers for strains SCC 1413, SCC 1631, SCC 1756 and SCC 2146 obtained in shake flask studies (50 ml of the current production medium in 250 ml erlenmeyer flasks, at 30° C, for 96 hours, at 300 rpm). The marked titer improvement (15 fold over the original parent, SCC 1413) is clearly demonstrated. Titters of 555-750 ug/ml (sum of the compound of Formula III and the nitroso derivative thereof) have been achieved in 100 liter fermentations using the current production medium with our best production strain, SCC 2146 (Table 7).

Strain		Titer (ug/ml)		Strain
Parent		Current		Parent
1413	100	100	100	1413
1631	100	100	100	1631
1756	100	100	100	1756
2146	100	100	100	2146

TABLE 5

Comparison of Strains SCC 1413 and SCC 1631 in FermentationsShowing Zones of Inhibition (mm) on Agar Plates¹TEST 1

<u>Strain</u> <u>SCC</u>	<u>S. aureus pH 7</u>		<u>E. coli pH 8</u>	
	<u>Undil.</u>	<u>1:20</u>	<u>Undil.</u>	
1631	28.7, 28.7	22.0	20, 17.5	
1413	28.7, 28.7	19.0	12 H ³ , 12 H ³	

TEST 2

<u>Strain</u> <u>SCC</u>	<u>S.aureus pH 7</u>		<u>E. coli pH 8</u>	
	<u>Undil.</u>	<u>1:20</u>	<u>Undil.</u>	
1631	28.1, 28.8	23.3, 23.1	14.8 C ² , 15.0 C ²	
1413	23.8, 23.1	20.5, 19.8	12 H ³ , 12 H ³	

1. Duplicate Determinations Where Appropriate

2. Clear Zone

3. Hazy Zone

Table 6

Flask Comparison of SCC's 1413, 1631, 1756 and 2146
Strains of Micromonospora Carbonacea var africana NRRL 15099, ATCC 39149
Titer of the compound of Formula III and Nitroso Analog (1A) Thereof (µg/ml)

<u>Culture</u>	<u>1 (NO₂)</u>	<u>1a (NO)</u>	<u>combined (1 + 1a)</u>
SCC 1413	5	3	8
SCC 1631	14	4	18
SCC 1756	17	16	33
SCC 2146	39	85	124

Table 7

100 Liter Fermentations of SCC 2146

Titer of Formula III and the NO Analog (1A) Thereof (µg/ml)

<u>Media</u>	<u>1 (NO₂)</u>	<u>1a (NO)</u>	<u>combined (1 + 1a)</u>
4I	105	315	420
4I	135	170	305
4I + 1/2Ni ³	55	500	555
4I + Ni ⁴	150	575	725
4I + 1/2Ni ³	100	650	750
4I + 1/2Ni ³	130	470	600

15 Footnotes to Table 7

1. The everminomycin-type antibiotic of Formula III.
2. The Nitroso analog of the antibiotic of Formula III.
3. Nickel concentration (1/2 Ni) = $2.5 \times 10^{-6}M$.
4. Nickel concentration Ni = $5 \times 10^{-6}M$.

The isolation of the lipophilic oligosaccharide antibiotic complex containing the compound of Formula III and the nitroso analog thereof was accomplished by use of the procedures of Example 4G of USP 4,597,968. The fermentation broth was adjusted to pH 7 and extracted twice with a volume of ethyl acetate two times the volume of the fermentation broth. The combined ethyl acetate extracts were concentrated and the amounts of the compound of Formula III and the nitroso analog thereof were determined by HPLC. The nitroso analog was converted into the nitro compound of Formula III by use of an oxidizing agent such as tertiary butyl hydroperoxide (t-BuO₂H) with vanadyl acetylacetonate dissolved in an aprotic organic solvent at room temperature. The course of the reaction was monitored by, for example, HPLC. The reaction mixture was quenched with trialkylphosphite and the crude product was purified by standard chromatographic techniques. e.g. silica gel column chromatography (acetone/CH₂Cl₂) or a column containing a polyhydroxyvinyl polymer such as Fractogel (Toyo Pearl) available from Toyo Haas, Philadelphia, Pennsylvania.

The pharmaceutically acceptable composition of matter of this invention may contain, in addition to (a) an antibiotic of Formula I, II, III, (b) at least a stoichiometric amount of a base capable of forming a pharmaceutically acceptable salt of such antibiotics and (c) an a specified amount of a binding agent, preferably recombinant human albumin, and (d) 0 weight percent (basis total weight of the composition) to about an iso-osmotic amount of a pharmaceutically acceptable tonicity agent and pharmaceutically acceptable carriers. The preferred pharmaceutically acceptable carriers include sterile water for injection and others that produce pharmaceutically acceptable compositions, i.e., compositions which when dissolved in a pharmaceutically acceptable carrier are substantially free of visible particles.

BIOLOGICAL ACTIVITIES

We have surprisingly found that the preferred composition of matter of this invention, comprising one mole of the compound represented by Formula III, 3 moles of NMG and 0.027 moles of human serum albumin, has substantially the same geometric mean MICs (GMM) against various bacteria, and substantially the same serum protein binding values as the compound of Formula III per se. It is expected that all the compositions of matter of this invention will behave similarly.

The in vitro antibacterial activity tests were performed via conventional agar dilution methods in Mueller - Hinton agar. The GMMs for the above-listed preferred composition of matter of this invention and for the compound of Formula III were determined against various bacteria, e.g., gram positive and gram negative bacteria. The term "susceptible gram positive and gram negative bacterial

infections" means a broad range of gram-positive bacterial infections, e.g., methicillin-resistant and methicillin-susceptible staphylococci, various strains of streptococci and enterococci and some gram-negative bacterial infections, e.g., Moraxella, Haemophilus, and Legionella. The compound of Formula III had excellent activity (2-fold more potent than vancomycin) against both methicillin-resistant staphylococci (GMM, 0.1 µg/ml) and methicillin-susceptible staphylococci (GMM, 0.5 µg/ml). The compound of Formula III also had good activity (similar to that of vancomycin) against Enterococcus faecalis and Enterococcus faecium (GMM, 0.49 µg/ml) and similarly good activity against enterococci resistant to vancomycin (MICs, ≥ 128 µg/ml) and good activity (MICs, ≤ 0.5 µg/ml) against various strains of streptococci. The compound of Formula III was very active against Borrelia burgdorferi (MICs, ≤ 0.49 µg/ml) and Legionella pneumophila and L. longbeacheae (MICs 2.5 µg/ml) but was only slightly active against gram-negative bacteria (GMM, ≥ 760 µg/ml), Trichomonas vaginalis (MICs, ≥ 192 µg/ml) and Mycoplasma sp. (MICs 200 µg/ml). No cross resistance with other antibiotics was observed.

The compound of Formula III had moderate bactericidal activity against various clinical and laboratory strains of staphylococci. The bactericidal activity of the compound of Formula III against staphylococci and enterococci was similar to that of vancomycin. The compound of Formula III had good activity against staphylococci in mice (PD₅₀ range 0.5 to 25.0 mg/kg), similar to that of vancomycin (0.7 to 28.5 mg/kg).

Following IV administration (30 mg/kg) of the compound of Formula III and 2 molecules of NMG, high serum levels were seen in rats (peak about 90 µg/ml) with a long serum beta half-life.

The pharmaceutically acceptable compositions of matter of this invention are expected to be active against the above-listed susceptible bacteria as well as against spirochetes including Treponema pallidum, anaerobes including Clostridium difficile as well as against Pneumocystis, Toxoplasma, protozoa and helminths.

Based on the activity of the compound of Formula III against Borrelia burgdorferi, Legionella pneumophila and L. longbeacheae, we expect that the compositions of matter containing the compound of Formula III will exhibit activity in humans against Lyme disease and legionnaire's disease.

The present invention provides a method of treating or preventing susceptible gram-positive and gram-negative bacterial infections in animals by administering to such animals especially man afflicted with such infections an amount or a pharmaceutical composition of the compositions of matter of this invention and a pharmaceutically acceptable carrier therefor.

The compositions of matter of this invention may be combined with any pharmaceutically acceptable carrier, e.g., non-ionic surfactants, sterilized water, aqueous ethanol, vegetable oils, or polyols, e.g., polyethylene glycols and propylene glycol and administered orally, parenterally or topically in a variety of formulations.

5 The use of sterile water for injection as a carrier is preferred. The sterile water for injection may optionally contain pharmaceutically acceptable substances, e.g., sodium chloride, potassium nitrate, glucose, mannitol, dextrose, sorbitol, xylitol or buffers such as phosphate, acetate or citrate as well as preservatives.

10 The compositions of matter of this invention are prepared by admixing a lipophilic oligosaccharide antibiotic of Formula I, II or III with at least about a stoichiometric amount of a base capable of forming a pharmaceutically acceptable salt thereof in a suitable solvent such as water and with a specified amount of a binding agent, for example human serum albumin. The order of admixing is not critical, but preferably an aqueous solution of the specific binding agent is admixed
15 with the base or alternatively it may be added after the base is admixed with the lipophilic oligosaccharide antibiotic and a tonicity agent such as mannitol. The formation of the aqueous solutions may take place at a temperature between 2° and 25°C. The aqueous solution so formed is filtered to produce a clear aqueous solution of the complex which may be evaporated or preferably freeze-dried to form
20 the compositions of matter of this invention in the form of a lyophilized powder which is readily reconstituted by addition of an amount of a pharmaceutically acceptable carrier such as sterile water for injection. The pharmaceutically acceptable non-ionic surfactant e.g. polysorbate-80, when used, would be added to the aqueous solution before filtration and lyophilization. Alternatively, the aqueous solution may be
25 frozen, thawed and thereafter filtered before use, e.g., as an intravenous IV formulation. It is a special feature of the present invention that the pharmaceutical compositions of the present invention form aqueous solutions and yet contain about 0.006 to about 0.03 mole, preferably about 0.027 mole of human serum albumin per mole of a compound of formula I, II or III. The discovery that pharmaceutical
30 compositions useful for safely and effectively delivering lipophilic oligosaccharide antibiotics to the serum of animals afflicted with susceptible bacterial infections, especially susceptible gram positive and gram negative bacterial infections, could be prepared by use of such a small amount of human serum albumin is particularly unexpected.

35 It is believed that even 0.006 moles of recombinant human serum albumin per mole of compound of formula I, II or III (substantially free of fatty acids and other impurities) will also be effective in the compositions of the present invention.

For oral administration, the compositions of this invention may be compounded in the form of tablets, capsules, elixers or the like. Tablets and capsules may contain such excipients as starch or lactose; liquid forms may contain coloring or flavoring agents. Topical preparations may be in the form of creams, hydrophobic and hydrophilic ointments, or aqueous, non-aqueous or emulsion-type lotions as well as pessaries or powders. Typical carriers for such formulations are water, oils, greases, polyesters and polyols. Parenteral formulations, e.g., injectable dosage forms, are usually liquids such as solutions or suspensions, with typical carriers being sterile water, saline solution and 5% by weight dextrose solutions. Parenteral formulations are preferred. Intravenous (IV) formulations are more preferred.

The dose to be administered in any particular dosage form will depend upon various factors, such as the weight, age and sex of the animal especially a mammal such as a human being being treated, the susceptibility of the infecting organism to the lipophilic oligosaccharide antibiotic, the stage and severity of the infection. Generally, the dosage of the lipophilic oligosaccharide antibiotics of Formula I, II or III administered is from about 1.0 mg to about 15 mg per kilogram of body weight, preferably about 3-5 mg per kilogram of body weight per day in divided dosages. The specified dosage is left to the discretion of the practitioner who will take into consideration the age and sex of the patient as well as, *inter alia*, the severity of the infection to be treated. IV administration is preferred.

In treating certain patients with the compositions of this invention, it is possible to include other pharmaceutically active ingredients in the same dosage unit.

EXAMPLES

EXAMPLE 1

A 100 liter fermentation of strain SCC 2146 of Micromonospora carbonacea var. africana NRRL 15099, ATCC 39149 improved as described hereinabove, was conducted in accordance with the procedures of Example 1B of USP 4,597,968 except that the following production medium (4I + 1/2Ni) was used and that the fermentation was conducted at 34°C for 24 hr followed by lowering the temperature to 30°C for the duration of the fermentation run, i.e., for another 72 hr (total fermentation time of 96 hr). Aeration and agitation rates were, 0.35 vvm and 350 rpm, respectively

Glucose	2.2% (weight)
PDP 650 dextrin	4.0% (weight)
Yeast Extract	0.5% (weight)
Meat Peptone	0.6% (weight)
Corn Steep Liquor	0.5% (volume)
Nickel Chloride	$2.5 \times 10^{-6} \text{M}$
Calcium Carbonate	0.4% (by weight)
Tap Water q.s. to give	1000ml

B. Isolation

Extract the fermentation broth of Example 1A twice with 200 L of ethyl acetate. Combine the ethyl acetate extracts and concentrate to provide a concentrated antibiotic complex containing a mixture of the compound of Formula III and the nitroso analog thereof (as determined by HPLC).

EXAMPLE 2

A) To 919g of antibiotic complex produced as described in Example 1 and containing 294g (32%) of a mixture of 3.4 moles of the nitroso analog to one mole of the compound of Formula III dissolved in 4.6 L of ethyl acetate, 68.8 g of NaHCO_3 and 2.98g of vanadyl acetylacetonate 3M in 2,2,4-trimethylpentane available from Aldrich (0.06 eq); 394 mL of 3M t-butylhydroperoxide was added to the so-formed mixture after a 1/2 hour period. Portions of 1.45g (0.03 eq) of vanadyl acetylacetonate were added thereto at 0 and after 1 1/2, 2 1/2, 3 1/2 and 4 hours so that 0.15 eq of vanadyl acetylacetonate was added over 4 hours. The reaction mixture was immersed in an ice bath, and 203 mL (0.5 eq) of triethylphosphite $(\text{C}_2\text{H}_5\text{O})_3\text{P}$ was added thereto. The so-formed reaction mixture was diluted with an equal amount of ethyl acetate while keeping the temperature of the reaction mixture at $\leq 30^\circ\text{C}$. The diluted ethyl acetate reaction mixture was washed twice with water. The aqueous layers were salted and extracted with ethyl acetate. The combined organic extracts were dried over MgSO_4 , filtered and concentrated. The so-formed residue was dissolved in a minimum amount of acetone and precipitated into 7 L of 1:9 (v/v) ethyl ether/hexane. The residue was filtered and washed with hexane dried under vacuum and heat to give 928g containing 30% (278g) of the nitro compound of Formula III.

B) The residue of Example 2A was purified on 5 kg of silica gel in a column. The column was eluted with 12 liters of CH_2Cl_2 containing successively 10%, 20%, 25%, 30%, 35% (v/v) of acetone. The appropriate fractions were combined and concentrated at $\leq 35^\circ\text{C}$. The so-formed residue was dissolved in acetone and precipitated into 10 parts of 10% ethyl ether/hexane. The product was

filtered and dried under vacuum without heat. The main fraction contained 147.5g of the compound of Formula III (98.7% pure). The other fractions contained crude product and were subjected to repeated silica gel chromatography until at least a 96-98 % pure product was obtained. The structure was determined by NMR and MS and found to be consistent with that of Formula III.

EXAMPLE 3

10 An aqueous solution containing 58.3g of manitol (USP and EP) and 42.0g of N-methyl glucamine ("NMG") USP and BP was prepared in 2.0L of water. To this solution was added 117g of the compound of Formula III followed by addition of 555g of 25% by weight HSA solution (Armour Pharmaceuticals). The so-formed solution was brought to a final volume of 2.9L. After agitation, a homogeneous solution containing 40mg per mL of the compound of Formula III was formed. The molar ratios of the three components were 1 mole of the compound of Formula III to 3 moles of "NMG" to 0.027 moles of HSA. The so-formed solution was filtered, filled into vials and freeze-dried to form a powder. For reconstitution of the powder to form a pharmaceutical composition, a pharmaceutically acceptable carrier such as sterile water for injection USP was added to the freeze-dried powder.

25 The safe and effective administration of the pharmaceutical composition of clear aqueous solutions of the homogeneous complex prepared in accordance with the procedures of this invention was tested in various in-vivo animal models by reconstituting the lyophilized powder with sterile water for injection to give solution containing 80 mg/mL of the compound of formula III such are reported in Tables 1 and 4.

30 A similar procedure may be used to prepare pharmaceutical compositions containing recombinant human albumin ("rHA") by replacing HSA with an equivalent amount of rHA.

EXAMPLE 4

35 A 100-mL aqueous solution containing 160 mg/mL of compound of Formula III and 57.6 mg/mL of NMG was prepared as a stock solution. To each 10mL of this solution was added 1.6, 3.2, 4.8, 6.4 and 8.0 mL of 25% human serum albumin solution and sterile water for injection was added to the so-formed solution to provide a solutions with a final volume of 20 mL containing 80 mg/mL of the compound of Formula III. The molar ratio of the three components were 1 mole-of the compound of Formula III to 3 moles of NMG to 0.006, 0.012, 0.018, 0.024 and

0.03 moles of HSA. The solutions so formed were filtered and used for animal testing.

EXAMPLE 5

This example provides the preparation of the composition used for the studies in rats and mice summarized in Table 1. The procedure of Example 3 was followed using the following ingredients in the listed amounts:

Ingredients	mg/Vial	% W/W ¹
Compound of formula III	200	33.5
NMG US and BP	72	12.1
HSA USP and EP	225	37.7
Mannitol USP, BP and EP	100	16.7
Water for injection USP	sublimed	---

1) The weight of each ingredient to the total weight of all ingredients.

The molar ratio of III:NMG:HSA was 1:3:0.027

The reconstituted solution was not iso-osmotic but use of a total of 200 or 300 mg of mannitol (instead of only 100 mg as used above) would likely render the solution iso-osmotic.

EXAMPLE 6

This example illustrates preparation of a composition such as used in Table 2 and containing 2 to 10% W/V based of a solution containing 80 mg/mL of the compound of formula III. The procedure of Examples 4 and 5 were followed to prepare a solution containing the compound of formula III, NMG and HSA in the molar ratio of 1:3: 0.006 to 0.03.

Human serum albumin
(HSA)

Broad Range Studied

mg HSA per 200 mg of compound of formula III	50-250
moles per one mole of III	0.006-0.03
mg/mL per 80 mg/mL of III	20-100
% w/v/ based on 80 mg/mL of the solution containing III	2-10%

5

EXAMPLE 7

This example provides compositions which may be prepared in accordance with the procedures of example 4 having a range of ingredients in compositions shown below.

10

<u>Ingredient</u>	<u>Broad Range</u> <u>Mg/200 mg. of III</u>	<u>Relative Molar Ratio</u> <u>based on one mole of III</u>
Compound of Formula III	200	1
NMG, USP and BP	48-144	2-6
HSA, USP and EP	50-250	0.006-0.03
Mannitol, USP, BP and EP	200-400	9.0-18
Sterile Water for injection USP	sublined	

Ingredient

Preferred Range

Molar Ratio

25


<u>Ingredient</u>	<u>Mg/200 mg. of III</u>	<u>based on one mole of III</u>
Compound of Formula III	200	1
NMG, USP and BP	72-84	3-3.5
HSA, USP and EP	150-250	.018-.03
Mannitol, USP, BP and EP	200-300	9.0-13.5
Sterile Water for Injection, USP	sublim,ed	

30


WHAT IS CLAIMED IS:

1. A composition of matter comprising:

(a) a lipophilic oligosaccharide antibiotic represented by Formula I;



wherein




X is one of NO₂, NO, NH₂, NHCOCH₃, NHOH, NH(C₂H₅), N(C₂H₅)₂, OH or H;

R₂ is one of CH₃, COCH(CH₃)₂, COCH₃, CO(CH₂)₃CH₃, COCH₂CH₃ or H;

R₃ is one of CH₃ or H;

R₄ is one of COCH₃, CH(OCH₃)(CH₃), CH(OH)CH₃, CHO, or H;



R_6 is CH_3 or H;

R_7 is CH_3 or H;

R_8 is CH_3 , CH_2OH or H

R_9 is CH_3 or H;

Y is OH, CH_3 , or H;

W is Cl or H; and

Z is Cl or H.

(b) at least about a stoichiometric amount of a base capable of forming a pharmaceutically acceptable salt with a lipophilic oligosaccharide antibiotic of Formula I;

(c) an amount of binding agent sufficient to achieve efficacious delivery of said lipophilic oligosaccharide antibiotic to the serum of an animal while simultaneously avoiding adverse reaction syndrome; and

(d) 0% by weight (basis, total weight in said composition) up to an iso-osmotic amount of a pharmaceutically acceptable tonicity agent.

2. The composition of claim 2 wherein the lipophilic oligosaccharide antibiotics represented by Formula 1 are selected from flambamycin, the everminomicins, the everminomicin-type antibiotics, curamycin, and the avilamycin A-N antibiotics.


3. The composition of claim 1, wherein the base is selected from chloroprocaine, procaine, piperazine, glucamine, N-methylglucamine, N,N-dimethylglucamine, ethylenediamine, diethanolamine, diisopropylamine, diethylamine, N-benzyl-2-phenylethylamine, N,N'-dibenzylethylenediamine, choline, clemizole, tris(hydroxymethyl)aminomethane, D-glucosamine or sodium hydroxide.

4. The composition of claim 1 wherein the base is N-methylglucamine.

5. The composition of claim 1 wherein the binding agent is HSA.

7. A composition of matter comprising:

- (a) a lipophilic oligosaccharide antibiotic represented by the Formula II



5

wherein X is one of NO₂, NO, NHOH, NH₂, NHCOCH₃, NHC₂H₅, N(C₂H₅)₂, OH or H


Y is OH or H

R₂ is H or CH₃R₃ is H

10

R₄ is H or CH(OCH₃)(CH₃)

and

R₅ is H or

15

- (b) at least about a stoichiometric amount of a base capable of forming a pharmaceutically acceptable salt with a lipophilic oligosaccharide antibiotic of Formula II;

- (c) an amount of a binding agent sufficient to achieve efficacious delivery of said lipophilic oligosaccharide antibiotic to the serum of an animal while simultaneously avoiding occurrence of adverse reaction syndrome; and

20

- (d) 0% by weight (basis, total weight of said composition) up to an iso-osmotic amount of up to an iso-osmotic amount a pharmaceutically acceptable tonicity agent.

8. The composition of claim 7 wherein the base is selected from chloroprocaine, procaine, piperazine, glucamine, N-methylglucamine, N,N'-dimethylglucamine, ethylenediamine, diethanolamine, diisopropylamine, diethylamine, N-benzyl-2-phenylethylamine, N,N'-dibenzylethylenediamine, choline, clemizole, tris(hydroxymethyl)aminomethane, D-glucosamine or sodium hydroxide.

9. The composition of claim 7 wherein the base is N-methylglucamine.


10. The composition of claim 7 wherein the binding agent is HSA.

11. The composition of claim 7 wherein the binding agent is rHA.

12. A composition of matter comprising:

- (a) the lipophilic oligosaccharide antibiotic represented by Formula III

15



20

- (b) at least about two equivalents of a base (per mole of the compound of Formula III) capable of forming a pharmaceutically acceptable salt of

25

said lipophilic oligosaccharide antibiotic of Formula III (c) an amount of a binding agent sufficient to achieve efficacious delivery of said lipophilic oligosaccharide antibiotic to the serum of an animal while simultaneously avoiding occurrence of adverse reaction syndrome; and (d) 0 % by weight (basis, total weight of said composition) of up to an iso-osmotic amount a pharmaceutically acceptable tonicity agent.

13. The composition of claim 8 wherein the base is selected from chloroprocaine, procaine, piperazine, glucamine, N-methylglucamine, N,N-dimethylglucamine, ethylenediamine, diethanolamine, diisopropylamine, diethylamine, N-benzyl-2-phenylethylamine, N,N'-dibenzylethylenediamine, choline, clemizole, tris(hydroxymethyl)aminomethane, D-glucosamine or sodium hydroxide.

14. The composition of claim 12 wherein the base is N-methylglucamine.

15. The composition of claim 12 wherein a tonicity agent is present.

16. The composition of claim 15 wherein the tonicity agent is mannitol.

17. The composition of claim 12 wherein the mole ratio of (a):(b):(c) is 1:about 2-6:about 0.006 to 0.030.

18. The composition of claim 12 wherein the binding agent is HSA.


19. The composition of claim 12 wherein the binding agent is rHA.

20.

A composition of matter comprising

(a) the lipophilic oligosaccharide antibiotic represented by
Formula III.

5



III

(b) at least about two equivalents of a base (per mole of said antibiotic of Formula III) capable of forming a pharmaceutically acceptable salt of said antibiotic of Formula III (c) an amount of recombinant human albumin sufficient to achieve efficacious delivery of said lipophilic oligosaccharide antibiotic to the serum of an animal while simultaneously avoiding occurrence of adverse reaction syndrome; and (d) an iso-osmotic amount of mannitol as a tonicity agent.

15

21. The composition of claim 20 wherein the base is N-methylglucamine.

22.

20 The composition of claim 20 wherein the iso-osmotic amount of mannitol is 35 to 45 % by weight of total composition.

23.

The composition of claim 20 wherein the molar ratio of (a):(b):(c) is 1:about 3-3.5: about 0.018 to 0.030.

25


24.

The composition of claim 20 wherein the binding agent is HSA

25. The composition of claim 20 wherein the binding agent is rHA.


26. A pharmaceutical composition for treating susceptible gram-positive and/or gram-negative bacterial infections comprising an antiinfective amount of a composition of matter of claim 20 and a pharmaceutically acceptable carrier thereof.

27. A method for treating susceptible gram-positive and/or gram-negative bacterial infections comprising administering to a mammal in need of such treating an antiinfective amount of a composition of matter of claim 20 or pharmaceutically composition thereof.



1/1

FIGURE



BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

national Application No
PCT/US 97/22518

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K47/48 A61K47/42 A61K38/38

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93-07904 A (SCHERING CORP) 29 April 1993 cited in the application	1-4,7-9, 12-17
Y	see abstract see tables 1-3 see page 16	1-27
X	JONES R N ET AL: "ANTIMICROBIAL ACTIVITY OF SCH 27899, OLIGOSACCHARIDE MEMBER OF THE EVERNIMOMYCIN CLASS WITH A WIDE GRAM-POSITIVE SPECTRUM" CLINICAL MICROBIOLOGY AND INFECTION, vol. 1, no. 1, 1995, pages 35-43, XP000652948	1-4,7-9, 12-17
Y	see table 1	1-27

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

*** Special categories of cited documents:**

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

Z document member of the same patent family

Date of the actual completion of the international search

22 May 1998

Date of mailing of the international search report

11. 06.98

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk

Authorized officer

INTERNATIONAL SEARCH REPORT

national Application No

PCT/US 97/22518

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>LORRAIN JM: "Antibiotiques: interaction avec d'autres médicaments" NOUV PRESSE MED, 12 NOV 1979, VOL. 8, NO. 44, PAGE(S) 3653-8, XP002065662 see abstract see page 3654</p>	1-27
Y	<p>GURKAN H ET AL: "Streptomycin sulphate microspheres: dissolution rate studies and release kinetics. I." J MICROENCAPSUL, JAN-MAR 1987, VOL. 4, NO. 1, PAGE(S) 39-46, XP002065663 see abstract see figures 3,5</p>	1-27
Y	<p>NAKASHIO S ET AL: "EVERNINOMICIN, A NEW OLIGOSACCHARIDE ANTIBIOTIC: ITS ANTIMICROBIAL ACTIVITY, POST-ANTIBIOTIC EFFECT AND SYNERGISTIC BACTERICIDAL ACTIVITY" DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, vol. 21, no. 1, 1995, pages 7-16, XP000653350 see abstract see tables 1,2</p>	1-27
Y	<p>GANGULY A K ET AL: "CHEMICAL MODIFICATION OF EVERNINOMICINS" JOURNAL OF ANTIBIOTICS, vol. 35, no. 5, May 1982, pages 561-570, XP000651703 see page 561</p>	1-27
Y	<p>EP 0 359 148 A (ISHIHARA MINING & CHEMICAL CO ;GREEN CROSS CORP (JP)) 21 March 1990 see abstract see examples</p>	1-27

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 97/22518

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 27 is directed to a method of treatment of the human/animal body, a search has been carried out, based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1-17 in part
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Claims Nos.: 1-17 in part

In view of the large number of compounds, which are defined by the general definition in claims 1-17, the search had to be restricted for economic reasons. The search was limited to the compounds for which pharmacological data was given and/or the compounds mentioned in the claims, and to the general idea underlying the application. (see Guidelines, Chapter III, paragraph 2.3).

1. The compound of claim 1, wherein the compound is a derivative of a known compound, and wherein the compound is a derivative of a known compound, and wherein the compound is a derivative of a known compound.

1. The compound of claim 1, wherein the compound is a derivative of a known compound, and wherein the compound is a derivative of a known compound, and wherein the compound is a derivative of a known compound.

INTERNATIONAL SEARCH REPORT


Information on patent family members

International Application No

PCT/US 97/22518

BEST AVAILABLE COPY

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9307904 A	29-04-1993	AT 156019 T	15-08-1997
		AU 678344 B	29-05-1997
		AU 2780692 A	21-05-1993
		CA 2121345 A	29-04-1993
		CN 1073359 A	23-06-1993
		DE 69221252 D	04-09-1997
		DE 69221252 T	22-01-1998
		EP 0538011 A	21-04-1993
		EP 0610295 A	17-08-1994
		ES 2104845 T	16-10-1997
		FI 941723 A	14-04-1994
		HR 921069 A	31-12-1994
		HU 75157 A	28-04-1997
		IL 103446 A	18-02-1997
		JP 2614407 B	28-05-1997
		JP 6510546 T	24-11-1994
		MX 9205922 A	31-08-1994
		NO 941276 A	08-04-1994
		NZ 244735 A	21-12-1995
		PL 170591 B	31-01-1997
		US 5624914 A	29-04-1997
		ZA 9207923 A	26-04-1993
EP 0359148 A	21-03-1990	JP 2078699 A	19-03-1990
		US 5116949 A	26-05-1992



UNITED STATES DEPARTMENT OF JUSTICE
FEDERAL BUREAU OF INVESTIGATION

June 17, 1964

MEMORANDUM FOR THE DIRECTOR

SUBJECT: [Illegible]

DATE: [Illegible]

TO: [Illegible]

FROM: [Illegible]

[Illegible text block]

[Illegible text block]

[Illegible text block]

[Illegible text block]

[Illegible text block]

[Illegible text block]



[Illegible text block]

[Illegible text block at the bottom of the page]